With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Funded by an unrestricted gift of $240,000 from Alumbra, a foundation established by philanthropist Christy Walton, the ...

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

South Korea is emerging as a key player in global pharmaceuticals, driven by an advanced healthcare ecosystem, strategic government initiatives, and ...

Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange SHANGHAI, Ap ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be ...

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to expand the use of vaccines against the respiratory syncytial virus (RSV) ...

The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...